Hendrik Bergsma

Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course

E. Krenning, C. V. van Eijck, D. Kwekkeboom, 2015, European Journal of Nuclear Medicine and Molecular Imaging.

Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate

E. Krenning, K. Mauff, D. Kwekkeboom, 2016, European Journal of Nuclear Medicine and Molecular Imaging.

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.

E. Krenning, R. Peeters, D. Kwekkeboom, 2012, Best practice & research. Clinical gastroenterology.

Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors

E. Krenning, M. Raaijmakers, D. Kwekkeboom, 2018, The Journal of Nuclear Medicine.

Therapy-related hematological malignancies after peptide receptor radionuclide therapy with 177Lu-DOTA-Octreotate: Incidence, course & predicting factors in patients with GEP-NETs

E. Krenning, D. Kwekkeboom, K. Lom, 2017 .

Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [177Lu-DOTA0,Tyr3]Octreotate

E. Krenning, D. Kwekkeboom, B. Kam, 2013, The Journal of Nuclear Medicine.

Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT

E. Krenning, M. Jong, R. Baum, 2016, European Journal of Nuclear Medicine and Molecular Imaging.